132 related articles for article (PubMed ID: 6338389)
1. Effects of naloxone in senile dementia: a double-blind trial.
Reisberg B; Ferris SH; Anand R; Mir P; Geibel V; De Leon MJ; Roberts E
N Engl J Med; 1983 Mar; 308(12):721-2. PubMed ID: 6338389
[No Abstract] [Full Text] [Related]
2. Low- and high-dose naloxone in dementia of the Alzheimer type.
Tariot PN; Sunderland T; Weingartner H; Murphy DL; Cohen MR; Cohen RM
Psychopharmacol Bull; 1985; 21(3):680-2. PubMed ID: 3898183
[No Abstract] [Full Text] [Related]
3. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
Acierno G
Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
[No Abstract] [Full Text] [Related]
4. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Wettstein A
Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
[TBL] [Abstract][Full Text] [Related]
5. Multicenter trial of naloxone in Alzheimer's disease.
Henderson VW; Roberts E; Wimer C; Bardolph EL; Chui HC; Damasio AR; Eslinger PJ; Folstein MF; Schneider LS; Teng EL
Ann Neurol; 1989 Apr; 25(4):404-6. PubMed ID: 2653175
[TBL] [Abstract][Full Text] [Related]
6. Choline in Alzheimer's disease.
Renvoize EB; Jerram T
N Engl J Med; 1979 Aug; 301(6):330. PubMed ID: 377082
[No Abstract] [Full Text] [Related]
7. Memory enhancement with oral physostigmine in Alzheimer's disease.
N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
[No Abstract] [Full Text] [Related]
8. Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
N Engl J Med; 1983 Sep; 309(9):555-6. PubMed ID: 6877328
[No Abstract] [Full Text] [Related]
9. Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls.
Sunderland T; Tariot PN; Mueller EA; Murphy DL; Weingartner H; Cohen RM
Psychopharmacol Bull; 1985; 21(3):676-9. PubMed ID: 3898182
[No Abstract] [Full Text] [Related]
10. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Ferris SH; Lucca U; Mohs R; Dubois B; Wesnes K; Erzigkeit H; Geldmacher D; Bodick N
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():34-8. PubMed ID: 9305514
[No Abstract] [Full Text] [Related]
11. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
12. Effects of physostigmine and lecithin on memory in Alzheimer disease.
Peters BH; Levin HS
Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of xantinolnicotinate in patients with dementia.
Kanowski S; Fischhof PK; Grobe-Einsler R; Wagner G; Litschauer G
Pharmacopsychiatry; 1990 May; 23(3):118-24. PubMed ID: 2197635
[TBL] [Abstract][Full Text] [Related]
14. Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.
Grossman F; Okamoto A; Turkoz I; Gharabawi G
J Am Geriatr Soc; 2004 May; 52(5):852-3. PubMed ID: 15086685
[No Abstract] [Full Text] [Related]
15. Oral physostigmine and lecithin improve memory in Alzheimer disease.
Thal LJ; Fuld PA; Masur DM; Sharpless NS
Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease).
Brinkman SD; Pomara N; Goodnick PJ; Barnett N; Domino EF
J Clin Psychopharmacol; 1982 Aug; 2(4):281-5. PubMed ID: 7119136
[No Abstract] [Full Text] [Related]
17. Naloxone and dementia.
Stowe C; Gora ML
Ann Pharmacother; 1993 Apr; 27(4):447-8. PubMed ID: 8477122
[No Abstract] [Full Text] [Related]
18. Effect of naltrexone on senile dementia of the Alzheimer type.
Hyman BT; Eslinger PJ; Damasio AR
J Neurol Neurosurg Psychiatry; 1985 Nov; 48(11):1169-71. PubMed ID: 3001233
[TBL] [Abstract][Full Text] [Related]
19. Lack of clinical benefit from naloxone in a dementia day hospital.
Panella JJ; Blass JP
Ann Neurol; 1984 Mar; 15(3):308. PubMed ID: 6721454
[No Abstract] [Full Text] [Related]
20. Assessment issues in clinical trials of tetrahydroaminoacridine and studies to alter decline in Alzheimer disease.
Thal LJ
Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S37-9. PubMed ID: 1781972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
